Here’s the latest CBD news:
- Reputable CBD brand Elixinol unveils a pet CBD tincture and edibles.
- Amazon is dropping marijuana screening from their pre-employment drug tests for qualifying positions.
- A Medical University of South Carolina trial points to depression and anxiety treatment potential of cannabidiol.
Table of Contents
- Elixinol Launches Pet CBD Line
- Amazon Doubles Down On Cannabis Reform Efforts With Relaxed Drug Screening Standards
- Recent Trial Further Confirms Mood-Regulating Effects of Cannabidiol
Elixinol Launches Pet CBD Line
CBD industry forerunner Elixinol has just unveiled a new line of pet CBD products, which marks their first foray into the pet CBD space.
Included in the collection, which is now live on the Elixinol website, are a tincture (Everyday Dog Drops) and two edibles (Calm and Active Mobility Dog Chews).
The tincture uses a broad-spectrum hemp extract featuring MCT (medium-chain triglyceride) coconut oil as a carrier and a non-detectable level of THC.
Between the two edible products, each of which provide five milligrams of CBD per piece, Elixinol has added ashwagandha, chamomile, and turmeric, which have been shown to promote improvements in mood and various forms of discomfort.
To learn more about the brand behind this recent launch and their other products, feel free to consult our comprehensive Elixinol review.
Amazon Doubles Down On Cannabis Reform Efforts With Relaxed Drug Screening Standards
This Tuesday (Sep 24), Amazon’s Senior Vice President of Human Resources, Beth Galetti, released an update on the company’s progress towards the promise they made in June to “exclude marijuana from our comprehensive pre-employment drug screening program.”
Per Galetti, in addition to making this change, which applies to job positions not beholden to Department of Transportation regulations, Amazon also “reinstated the employment eligibility for former employees and applicants who were previously terminated or deferred during … marijuana screenings.”
The post cites a commitment to social equity as justification for these changes, referencing public data that points to the disproportionate impact of marijuana testing on communities of color.
Amazon has also been an active supporter of various pieces of pro-cannabis legislation, such as the Marijuana Opportunity Reinvestment and Expungement Act of 2021 (MORE) and the Cannabis Administration and Opportunity Act.
Recent Trial Further Confirms Mood-Regulating Effects of Cannabidiol
Results from a new trial conducted by the Medical University of South Carolina connected medicinal cannabis use with “lower self-reported depression … superior sleep, quality of life, and less pain on average.”
In the 538-participant trial (368 cannabis users, 170 in control group), researchers administered an online survey designed to detect and measure anxiety and depression symptoms, frequency of cannabis use, quality of life, and chronic pain.
After the survey, respondents were invited back for follow-up surveys at 3-month intervals, with the aim being a closer look at the effects of cannabis on these issues in those that continued or re-initiated use.
As mentioned, cannabis use improved sleep, quality of life, pain, and self-reported depression level at the baseline (initial survey), but improvements in anxiety symptoms were only reported in those who initiated medical cannabis use during the follow-up period.
The authors concluded that medical cannabis shows great promise to treat these issues in a clinical setting, but “future placebo-controlled studies are necessary to replicate these findings and determine the route of administration, dose, and product formulation characteristics to optimize clinical outcomes.”